ロード中...

PI-3 kinase p110β: a therapeutic target in advanced prostate cancers

Prostate cancers in the castration-resistant stage are life-threatening because they are not curable in clinic. The novel androgen receptor inhibitor Xandi (Enzalutamide) and the new CYP17 inhibitor Zytiga (Abiraterone) prolonged patient survival only a few months in advanced prostate cancers. There...

詳細記述

保存先:
書誌詳細
出版年:Am J Clin Exp Urol
主要な著者: Li, Benyi, Sun, Aijing, Jiang, Wencong, Thrasher, J Brantley, Terranova, Paul
フォーマット: Artigo
言語:Inglês
出版事項: e-Century Publishing Corporation 2014
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4219313/
https://ncbi.nlm.nih.gov/pubmed/25374921
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!